Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study

Li, Runmei; Wang, Changli; Liu, Liang; Du, Chenxing; Cao, Shui; Yu, Jinpu; Wang, Shizhen Emily; Hao, Xishan; Ren, Xiubao; Li, Hui

doi:10.1007/s00262-012-1260-2

Cited by 97 publications

(83 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, after 5 courses, immune function improvement rates could all be over 70%, consistent with the report of Li et al (2012) on kidney cancer immune function improvement. This study suggested that the improvements of immune function by CIK cells were affected by two factors, the first factor was the situation of immune function of lung cancer patients prior to the treatment, different immune functional status would react differently to CIK therapy.…”

Section: Discussionsupporting

confidence: 78%

Moderating Effects and Maintenance of Lung Cancer Cellular Immune Functions by CIK Cell Therapy

Jin¹,

Chen²,

Li³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Aims: To study the CIK cell treatment effects on regulation of cellular immune function disorders in patients with lung cancer, and to analyze the time characteristics. Methods: Cellular immune function was assessed by FCM, and patients with functional disorders were randomly divided into two groups, one given CIK cell therapy within 18 months (5 courses) and the other the controls, which were followed up for 1 year with cellular immune functions tested once a month. Results: There were 5 types of cellular immunity, 4 of which are disorders; after CIK treatment, the improvement rate of the 4 groups were 79.1%, 70.8%, 76.0% and 70.0%, intergroup differences not being statistically significant (P=0.675), all significantly higher than in the control group (P=0.000). The median maintenance times for the 4 groups were 10.4 months (9.76-11.04), 8.4 months (7.86-8.94), 9.8 months (9.20-10.4) and 7.9 months (6.25-9.55), respectively. Conclusions: CIK cells were able to improve the immune functions of patients with lung cancer, the rate of improvement and maintenance time being related to the immune function before the treatment and CIK-cell-therapy courses.

show abstract

Section: Discussionsupporting

confidence: 78%

Moderating Effects and Maintenance of Lung Cancer Cellular Immune Functions by CIK Cell Therapy

Jin¹,

Chen²,

Li³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…On the other hand, CIK cell infusion can improve the immune function of patients, which was consistent with other studies [27][28][29][30], indicating that maintaining and enhancing immune functions played a crucial role in improving quality of life and survival in lung cancer patients. There was only 1 case of mild fever in treatment group after treatment, while the patient could relieve by symptomatic treatment.…”

Section: Discussionsupporting

confidence: 78%

Effect of Chinese Medicine XIAOJI Decoction Combined with Platinum-Based Chemotherapy and Transfusion of Cytokine-Induced Killer Cells in Patients with Stage III B/IV Non-Small Cell Lung Cancer

Li¹,

Liu²

2015

J Drug Metab Toxicol

View full text Add to dashboard Cite

“…This result is similar to the findings of Li et al, who also report that CIK cell treatment can improve the efficacy of chemotherapy in NSCLC patients. 24 More importantly, our results suggested that patients who received alternate CIK and NK cells treatment exhibited a better prognosis than those who received CIK cells only. These results indicate that adjuvant CIT, especially with the alternate application of CIK and NK cells, can improve the clinical outcome of NSCLC patients.…”

Section: Discussionmentioning

confidence: 49%

“…Indeed, previous studies have increasingly confirmed the positive clinical efficacy of CIT in the treatment of NSCLC. [22][23][24][25][26] However, to date, the patterns of CIT have been rarely reported. Therefore, in the present study, through a retrospective analysis of 120 patients with NSCLC, we not only validated the efficacy of adjuvant CIT combined with chemotherapy, but also found that the efficacy of adjuvant CIT with alternate application of CIK and NK cells were superior to that of adjuvant CIT with CIK cells only.…”

Section: Discussionmentioning

confidence: 99%

“…A series of clinical studies have shown that adjuvant CIT, such as CIK cells and NK cells, can lead to promising antitumor effects on various cancers, [17][18][19][20][21] including lung cancer. 3,[22][23][24][25][26] Several reviews and meta-analysis reports have also demonstrated the safety and effectiveness of adjuvant CIT in clinics. [27][28][29][30] However, the patterns of CIT require thorough investigation in order to achieve optimal outcome and cost-effectiveness.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer

et al. 2015

View full text Add to dashboard Cite

Postoperative non-small cell lung cancer (NSCLC) patients require adjuvant therapy to improve their prognosis. In this study, we investigated the efficacy of a sequential combination of autologous cellular immunotherapy (CIT) and chemotherapy for postoperative NSCLC. This retrospective study included 120 postoperative NSCLC patients: 60 cases received only chemotherapy; 33 cases received chemotherapy and sequential CIT with cytokine-induced killer (CIK) cells; and 27 cases received chemotherapy and sequential CIT with alternate CIK and natural killer (NK) cells. Survival analysis showed significantly higher overall survival rates in the CIT group compared with the control group. Overall survival was higher in patients who received CIT with alternate CIK and NK cells than those who received treatment with only CIK cells. Multivariate analysis showed that adjuvant CIT was an independent prognostic factor for overall survival of patients with NSCLC. In subgroup analyses, adjuvant CIT significantly improved the overall survival of patients with less than 60 y old and positive lymph node. In conclusions, these data indicate that adjuvant CIT, especially with alternate application of CIK and NK cells, is an effective therapeutic approach to prolong survival of patients with NSCLC, particularly for patients 60 y old with positive lymph nodes.

show abstract

Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study

Cited by 97 publications

References 33 publications

Moderating Effects and Maintenance of Lung Cancer Cellular Immune Functions by CIK Cell Therapy

Moderating Effects and Maintenance of Lung Cancer Cellular Immune Functions by CIK Cell Therapy

Effect of Chinese Medicine XIAOJI Decoction Combined with Platinum-Based Chemotherapy and Transfusion of Cytokine-Induced Killer Cells in Patients with Stage III B/IV Non-Small Cell Lung Cancer

Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer

Contact Info

Product

Resources

About